These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33731883)

  • 1. Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.
    Fokoun C; Serrier H; Rabier H; Goutelle S; Tod M; Bourguignon L
    Pharmacogenomics J; 2021 Oct; 21(5):559-565. PubMed ID: 33731883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.
    Mosikian A; Dolgorukova A; Zalevskaya A
    Pharmacogenomics; 2016 Dec; 17(18):2115-2126. PubMed ID: 27885968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
    Holstein A; Hahn M; Patzer O; Seeringer A; Kovacs P; Stingl J
    Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
    Dujic T; Zhou K; Donnelly LA; Leese G; Palmer CNA; Pearson ER
    Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.
    Muhammad SD; Khan H; Hussain M; Zeb TF; Kumar D; Rahi R; Asif M; Balooch AA
    Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1771-1777. PubMed ID: 33612460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes.
    Wang K; Yang A; Shi M; Tam CCH; Lau ESH; Fan B; Lim CKP; Lee HM; Kong APS; Luk AOY; Tomlinson B; Ma RCW; Chan JCN; Chow E
    Clin Pharmacol Ther; 2022 Feb; 111(2):461-469. PubMed ID: 34656068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
    Sullivan SD; Alfonso-Cristancho R; Conner C; Hammer M; Blonde L
    Pharmacotherapy; 2009 Nov; 29(11):1280-8. PubMed ID: 19873688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
    Vaughan EM; Rueda JJ; Samson SL; Hyman DJ
    Curr Diabetes Rev; 2020; 16(8):851-858. PubMed ID: 32026779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.